GMP Warning Letter: Teva Preempts FDA In Disclosing Problems At Jerusalem Plant
Executive Summary
Generic giant Teva took the unusual step of disclosing the entire contents of a Jan. 31 FDA warning letter about good manufacturing process failings, as part of a Securities and Exchange Commission filing it posted online two days later.
You may also be interested in...
New Teva CEO’s Initial Priorities Are Manufacturing, Copaxone, R&D
Teva’s new CEO, Jeremy Levin, has been emphasizing manufacturing efficiency, global compliance and a more focused R&D structure in initial comments to Wall Street.
Teva’s U.S. Generic Sales Rebound With Late-Year Launches, Ranbaxy Lipitor Deal
The Israel-based manufacturer saw its full-year U.S. generic revenues drop 32% due to expired marketing exclusivities and manufacturing problems at two plants. However, the fourth quarter brought a rebound, thanks to launches of generic Zyprexa and Combivir and a profit-sharing agreement on atorvastatin.
Did Aurobindo Destroy Its Credibility With FDA Along With A Microbial Plate?
A U.S. FDA warning letter coming on top of an import alert suggests the agency doesn't trust India-based Aurobindo Pharma's quality control